AIDX

DEFA14A - 20/20 Biolabs, Inc. (0001139685) (Filer)

8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)

424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)

424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)

8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)

Best Quarter of Flagship Multi-Cancer Early Detection Testing; OneTest™ Revenue Increased 47% Year-Over-Year to $0.7 Million; Gross Profit Increased 87% to $0.3 Million, with Gross Margin Expanding to 41.7% from 30.5% Company Expands OneTest™ Across Firefighter, Occupational Health, Military, and Physician Practice Markets Cash Position Strengthened to $4.5 Million as of June 30, 2026, with All Convertible Note Debt Eliminated During the Quarter GAITHERSBURG, Md., Aug. 17, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic d

8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)

Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetings in Taipei, Tokyo, and Seoul Webinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., July 30, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 BioLabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, August 5, 2026, at 12:00 p.m. Eastern time. Jonathan Cohen, Chief Executive Officer of 20/20 BioLabs, will discuss the Company’s rec

Management Met with Potential Acquisition, Licensing, Joint Venture, and Commercial Partners Across the Region Initiative Aims to Expand Mission of Saving Lives Through Early Detection and Prevention of Cancers and Chronic Diseases GAITHERSBURG, Md., July 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that members of its management team participated in BIO Asia-Taiwan July 15-19 and held strategic meetings in Taipei, Tokyo, and Seoul with companies, investors, laboratories, preventat

Agreement Temporarily Restricts Preferred-to-Common Stock Conversions Below a Defined Price Threshold, Mitigating Potential Near-Term Dilution GAITHERSBURG, Md., July 23, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) (the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into a standstill agreement (the "Agreement") with Streeterville Capital, LLC ("Streeterville") relating to the Company’s outstanding Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The Agreement became effective on July 16, 2026. Under the terms of

8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)

Company Outlines Strategy to Position OneTest™ as the First Affordable, Multi-Cancer Early Detection Blood Test for Earlier Stage Detection GAITHERSBURG, Md., July 09, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) (the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today highlighted key themes from its inaugural investor webinar held on July 1, 2026. The Company presented its strategy for advancing OneTest™ for Cancer toward potential Medicare reimbursement under the new statutory pathway for FDA-authorized multi-cancer early detection ("MCED") blood tests beginning in 202

8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)

DEFA14A - 20/20 Biolabs, Inc. (0001139685) (Filer)

DEF 14A - 20/20 Biolabs, Inc. (0001139685) (Filer)

Inaugural Session to be Held Wednesday, July 1, 2026, at 12:00 p.m. ET Recurring Forum Intended to Increase Transparency, Strengthen Shareholder Communication, and Provide Investors with Direct Access to Management GAITHERSBURG, Md., June 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced the launch of a recurring monthly investor webinar series designed to keep shareholders and the broader investment community informed on the Company’s latest developments and progress. The inaugural web

PRE 14A - 20/20 Biolabs, Inc. (0001139685) (Filer)

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that its OneTest™ multi-cancer early detection blood ("MCED") test has been selected as part of a firefighter cancer screening initiative for the state of Vermont in partnership with National Diagnostic Services ("NDS"). NDS will provide ultrasound services and medical oversight in

8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)

Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed  GAITHERSBURG, Md., May 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (Nasdaq: AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced that it is developing contingency plans to establish Ebola and Hantavirus testing in its CAP-accredited CLIA laboratory if called upon to support or augment testing by public health laboratories. Early in the COVID-19 pandemic, 20/20 Biolabs was among the first companies in the U.S. to import, validate, and dis

424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)

424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)

10-Q - 20/20 Biolabs, Inc. (0001139685) (Filer)

8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)

State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March 31, 2026 Recent Strategic Wins Include Evexia Diagnostics Distribution Agreement, ROKIT Healthcare CKD License, and Commercial Launch of OneTest™ for Longevity GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported its financial and operational results for the first quarter ended March